Houédé N, Pourquier P [Molecular signatures in castration-resistant prostate cancers: An update]. Bull Cancer. 2022-07-21. doi:10.1016/j.bulcan.2022.06.007
Houédé N, Flahault C, Gross-Goupil M, Le Clanche S, Le Goff Y, Merlier F, Pignot G, Pourroy B, Thibault C, Xylinas E, Solbes M-N, Dénéchère G [Locally advanced or metastatic bladder cancer: Identification of barriers and levers of patients' pathway in France]. Bull Cancer. 2022-06-17. doi:10.1016/j.bulcan.2022.04.010
Rollin P, Xylinas E, Lanz C, Audenet F, Brunelle S, Masson-Lecomte A, Pignot G, Roumiguié M, Méjean A, Neuzillet Y [Intravesical adjuvant regimen of epitubicin for intermediate risk NMIBC: Feasability study from CC-AFU vessie]. Prog Urol. 2022;32(5):326-331. doi:10.1016/j.purol.2021.12.008
Cuenant A, Eglin I, Ferreira V, Houédé N [Development of a therapeutic education program for prostate cancer patients undergoing new generation hormone therapy]. Bull Cancer. 2022;109(5):623-629. doi:10.1016/j.bulcan.2021.11.014
Leenhardt F, Gauthier L, Alexandre M, Guiu S, Firmin N, Viala M, Lossaint G, Gautier C, Mollevi C, Gracia M, Mbatchi L, Evrard A, Jacot W Pharmacokinetic Variability Drives Palbociclib-Induced Neutropenia in Metastatic Breast Cancer Patients: Drug-Drug Interactions Are the Usual Suspects. Pharmaceutics. 2022;14(4):841. doi:10.3390/pharmaceutics14040841
Vano Y-A, Bennamoun M, Chevreau C, Borchiellini D, Pannier D, Maillet D, Gross-Goupil M, Tournigand C, Laguerre B, Barthélémy P, Coquan E, Cancel M, Huillard O, Beuzeboc P, Fournier L, Méjean A, Cathelineau X, Doumerc N, Paparel P, Bernhard J-C, de la Taille A, Bensalah K, Tricard T, Waeckel T, Pignot G, Braychenko E, Caruso S, Sun C-M, Verkarre V, Lacroix G, Moreira M, Meylan M, Bougouïn A, Phan L, Thibault-Carpentier C, Zucman-Rossi J, Fridman W, Sautès-Fridman C, Oudard S Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial. Lancet Oncol. 2022;23(5):612-624. doi:10.1016/S1470-2045(22)00128-0
Kong-Hap M-A, Andrade A, Del Rio M, Pasero P, Theillet C, Gongora C, Pourquier P Multiplexed-Based Assessment of DNA Damage Response to Chemotherapies Using Cell Imaging Cytometry. Int J Mol Sci. 2022;23(10):5701. doi:10.3390/ijms23105701
Viganò L, Locatelli A, Ulisse A, Galbardi B, Dugo M, Tosi D, Tacchetti C, Daniele T, Gy?rffy B, Sica L, Macchini M, Zambetti M, Zambelli S, Bianchini G, Gianni L Modulation of the Estrogen/erbB2 Receptors Cross-talk by CDK4/6 Inhibition Triggers Sustained Senescence in Estrogen Receptor- and ErbB2-positive Breast Cancer. Clin Cancer Res. 2022;28(10):2167-2179. doi:10.1158/1078-0432.CCR-21-3185
Italiano A, Cassier P, Lin C-C, Alanko T, Peltola K, Gazzah A, Shiah H-S, Calvo E, Cervantes A, Roda D, Tosi D, Gao B, Millward M, Warburton L, Tanner M, Englert S, Lambert S, Parikh A, Afar D, Vosganian G, Moreno V First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma. Cancer Immunol Immunother. 2022;71(2):417-431. doi:10.1007/s00262-021-02973-w
Siefker-Radtke A, Necchi A, Park S, Huddart R, Burgess E, Fleming M, Rezazadeh Kalebasty A, Mellado B, Varlamov S, Joshi M, Duran I, Tagawa S, Zakharia Y, Akapame S, Santiago-Walker A, Monga M, O'Hagan A, Loriot Y Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study. Lancet Oncol. 2022;23(2):248-258. doi:10.1016/S1470-2045(21)00660-4
Smith M, Hussain M, Saad F, Fizazi K, Sternberg C, Crawford E, Kopyltsov E, Park C, Alekseev B, Montesa-Pino Á, Ye D, Parnis F, Cruz F, Tammela T, Suzuki H, Utriainen T, Fu C, Uemura M, Méndez-Vidal M, Maughan B, Joensuu H, Thiele S, Li R, Kuss I, Tombal B Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. N Engl J Med. 2022;386(12):1132-1142. doi:10.1056/NEJMoa2119115
Vano Y-A, Phan L, Gravis G, Schlürmann F, Maillet D, Bennamoun M, Topart D, Borchiellini D, Ratta R, Ryckewaert T, Hasbini A, Hans S, Emambux S, Cournier S, Braychenko E, Elaidi R-T, Oudard S Cabozantinib-nivolumab sequence in metastatic renal cell carcinoma: The CABIR study. Int J Cancer. 2022;151(8):1335-1344. doi:10.1002/ijc.34126
Xiong H, Mancini M, Gobert M, Shen S, Furtado G, Lira S, Parkhurst C, Brengues M, Tadokoro C, Trimarchi T, Singh A, Khiabanian H, Minuzzo S, Indraccolo S, Lobry C, Aifantis I, Herranz D, Lafaille J, Maraver A Spleen plays a major role in DLL4-driven acute T-cell lymphoblastic leukemia. Theranostics. 2021;11(4):1594-1608. doi:10.7150/thno.48067
Matheux A, Gassiot M, Fromont G, Leenhardt F, Boulahtouf A, Fabbrizio E, Marchive C, Garcin A, Agherbi H, Evrard A, Houédé N, Balaguer P, Gongora C, Mbatchi L, Pourquier P PXR Modulates the Prostate Cancer Cell Response to Afatinib by Regulating the Expression of the Monocarboxylate Transporter SLC16A1. Cancers (Basel). 2021;13(14):3635. doi:10.3390/cancers13143635
Pourquier P Inventaire des lésions de l'ADN et principaux mécanismes de réparation de l'ADN. Bull Cancer. 2021;108(3):234-235. doi:10.1016/j.bulcan.2020.10.016
Corvaglia V, Ait Mohamed Amar I, Garambois V, Letast S, Garcin A, Gongora C, Del Rio M, Denevault-Sabourin C, Joubert N, Huc I, Pourquier P Internalization of Foldamer-Based DNA Mimics through a Site-Specific Antibody Conjugate to Target HER2-Positive Cancer Cells. Pharmaceuticals (Basel). 2021;14(7):624. doi:10.3390/ph14070624
Larbouret C, Gros L, Pèlegrin A, Chardès T Improving Biologics' Effectiveness in Clinical Oncology: From the Combination of Two Monoclonal Antibodies to Oligoclonal Antibody Mixtures. Cancers (Basel). 2021;13(18):4620. doi:10.3390/cancers13184620
Harter V, Gravis G, Fléchon A, Chevreau C, Mahammedi H, Laguerre B, Guillot A, Joly F, Abadie-Lacourtoisie S, Geoffrois L, Fiore F, Roubaud G, Barthélémy P, Voog E, Emambux S, Serrate C, Saldana C, Nguyen-Tan-Hon T, Loriot Y, Eymard J-C, Huillard O, Houédé N, Spano J-P, Demery M, Vieillot S, L'Haridon T, Hilgers W, Allory Y, Pfister C Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial. Clin Genitourin Cancer. 2021;19(6):554-562. doi:10.1016/j.clgc.2021.08.005
Ragimbeau R, El Kebriti L, Sebti S, Fourgous E, Boulahtouf A, Arena G, Espert L, Turtoi A, Gongora C, Houédé N, Pattingre S BAG6 promotes PINK1 signaling pathway and is essential for mitophagy. FASEB J. 2021;35(2):e21361. doi:10.1096/fj.202000930R
Fohlen A, Bordji K, Assenat E, Gongora C, Bazille C, Boulonnais J, Naveau M, Breuil C, Pérès E, Bernaudin M, Guiu B Anticancer Drugs for Intra-Arterial Treatment of Colorectal Cancer Liver Metastases: In-Vitro Screening after Short Exposure Time. Pharmaceuticals (Basel). 2021;14(7):639. doi:10.3390/ph14070639
Rabia E, Garambois V, Hubert J, Bruciamacchie M, Pirot N, Delpech H, Broyon M, Theillet C, Colombo P-E, Vie N, Tosi D, Khellaf L, Jarlier M, Radosevic-Robin N, Chardès T, Pèlegrin A, Larbouret C Anti-tumoral activity of the Pan-HER (Sym013) antibody mixture in gemcitabine-resistant pancreatic cancer models. MAbs. 2021;13(1):1914883. doi:10.1080/19420862.2021.1914883
Chauvin M, Garambois V, Choblet S, Colombo P-E, Chentouf M, Gros L, De Brauwere D-P, Dumas K, Robert B, Jarlier M, Martineau P, Navarro-Teulon I, Pépin D, Chardès T, Pèlegrin A Anti-Müllerian hormone concentration regulates activin receptor-like kinase-2/3 expression levels with opposing effects on ovarian cancer cell survival. Int J Oncol. 2021;59(1):43. doi:10.3892/ijo.2021.5223
Chauvin M, Garambois V, Colombo P-E, Chentouf M, Gros L, Brouillet J-P, Robert B, Jarlier M, Dumas K, Martineau P, Navarro-Teulon I, Pépin D, Chardès T, Pèlegrin A Anti-Müllerian hormone (AMH) autocrine signaling promotes survival and proliferation of ovarian cancer cells. Sci Rep. 2021;11(1):2231. doi:10.1038/s41598-021-81819-y
Creusot N, Gassiot M, Alaterre E, Chiavarina B, Grimaldi M, Boulahtouf A, Toporova L, Gerbal-Chaloin S, Daujat-Chavanieu M, Matheux A, Rahmani R, Gongora C, Evrard A, Pourquier P, Balaguer P The Anti-Cancer Drug Dabrafenib Is a Potent Activator of the Human Pregnane X Receptor. Cells. 2020;9(7):E1641. doi:10.3390/cells9071641
Re?nik L-M, Cantelli C, Fersing C, Gongora C, Pouget J-P, Lisowski V Synthesis and in vitro antitumour activity of carboplatin analogues containing functional handles compatible for conjugation to drug delivery systems. Bioorg Med Chem Lett. 2020;30(22):127527. doi:10.1016/j.bmcl.2020.127527
Institut de Recherche en Cancérologie de
